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Abstract Recent studies have found that the risk of death
continues to increase among female smokers, as compared
with women who have never smoked. We wanted to
examine the effect of smoking on all-cause and cause-
specific mortality and calculate the corresponding popula-
tion attributable fraction (PAF) of mortality in the Nor-
wegian women and cancer study; a nationally
representative prospective cohort study. We followed
85,320 women, aged 31–70 years, who completed a
questionnaire in 1991–1997, through linkages to national
registries through December 2008. Questionnaire data
included information on lifestyle factors, including lifetime
history of smoking. Poisson regression models were fitted
to estimate relative risks (RRs) with 95 % confidence
intervals (CIs) adjusting for age, birth cohort, education,
postmenopausal status, alcohol consumption and body
mass index, all at enrollment. During a mean follow-up
time of 14 years 2,842 deaths occurred. Compared with
that of never smokers, current smokers had a mortality rate
that was double (RR = 2.34; 95 % CI 2.13–2.62) from
deaths overall, triple (RR = 3.30; 95 % CI 2.21–4.82)
from cerebrovascular disease and myocardial infarction
(RR = 3.65; 95 % CI 2.18–6.15), 12 times (RR = 12.16;
95 % CI 7.80–19.00) from lung cancer and seventeen times
(RR = 17.00; 95 % CI 5.90–48.78) from chronic
obstructive pulmonary diseases. The PAF of mortality due
to smoking was 34 % (CI 30–39). In summary, one in three
deaths among middle aged women in Norway could have
been prevented if the women did not smoke. More middle-
aged women, than ever before, are dying prematurely due
to smoking in Norway.
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Introduction
Worldwide, tobacco use causes annually more than five
million deaths, or one death every 6 seconds. Unless cur-
rent smokers stop smoking before or during middle age,
this number is expected to rise to eight million or more by
the year 2030 [1–3]. In spite of the overwhelming evidence
of the detrimental effects of smoking on health [4, 5], the
tobacco use among women is rising globally and the age of
initiation of daily smoking among women seems to have
become as young as it is in men [6, 7].
For women in Norway, the prevalence of daily smokers
was 23 % in 1954, the peak was at 37 % in 1970 and then
it stabilized at around 32 % for the rest of the century [8].
The decline among female smokers first started in the
twentyfirst century [9]. As a consequence the lung cancer
incidence and mortality rates have both been increasing for
Norwegian women. In fact, the strongest increase in cancer
incidence from the past 5-year period (2001–2005) until
the current one (2006–2010) occurred in lung cancer (16%)
[10]. The four tobacco epidemic stages model suggested by
Lopez et al. almost 20 years ago described the effects on
mortality of the cigarette epidemic in Western countries
such as the USA, UK and Australia. The rise and fall in
female smoking and in smoking-attributed mortality usu-
ally lagged behind that in men by about 20–30 years [11].
Recent studies have found that for women the risk of
death from cigarette smoking continues to increase result-
ing in a population attributable fraction (PAF) of mortality
that is larger than previously reported [4, 12–15].
As pointed out by Oza et al. [16], estimating the number
of deaths attributable to smoking is needed for priority
setting and monitoring the disease burden associated with
this risk factor in different populations.
Today, the majority of middle-aged Norwegian women
are either former or current smokers, who started to smoke
in their teens [17]. We wanted to estimate the effects of
cigarette smoking on all-cause and cause-specific mortality
and estimate the proportion of deaths attributable to
smoking in the Norwegian Women and Cancer (NOWAC)
study, a nationally representative prospective cohort study.
Materials and methods
Study population
The NOWAC study is a nationally representative pro-
spective cohort study comprising a sample of the Norwe-
gian middle-aged female population. The cohort profile has
been previously described in detail [18, 19]. Briefly, a
random sample of women was selected from the central
population register according to year of birth. These
women were sent a letter of invitation to participate in the
study, which also contained a questionnaire, and a pre-
stamped return envelope. The National Data Inspectorate
and the Regional Committee for Medical Research Ethics
approved the study. All women gave an informed consent
(http://site.uit.no/kvinnerogkreft).
The inclusion criteria for the present study were women
born from 1926 to 1965, who during 1991–1997 completed
an initial questionnaire, containing questions on life style
factors as smoking and alcohol consumption (N = 95,947).
The overall response rate was 57 %. Women who emi-
grated or died (N = 22) before the start of follow-up were
excluded. We excluded 10,605 women due to missing
information on either smoking status (N = 2,224) or any of
the co-variables (education, BMI, menopausal status and
alcohol consumption) under study. Altogether 458 women
with missing information had died during follow-up of
which 64 (14 %) had missing information on smoking
status. The analytical cohort comprised the remaining
85,320 women with complete information in the multi-
variable analyses. Compared with the women in the ana-
lytical cohort, the women that were excluded due to
missing information were on average 2.7 years older, but
were similar according to education, BMI and alcohol
consumption (data not shown).
Exposure information
The baseline questionnaire included a detailed assessment
of lifetime smoking history. The questionnaires asked if the
women had ever smoked, and those answering ‘‘yes’’ were
asked the number of cigarettes smoked daily at different
ages. Subsequently, they were asked if they currently
smoked on a daily basis. We categorized ever smokers
according to current and former smoking status at enroll-
ment. All women who were neither current nor former
daily smokers were classified as never smokers. The
baseline questionnaires also asked about years of educa-
tion, height and current weight (allowing us to calculate
body mass index, BMI, kg/m2), menopausal status (pre-,
peri-, postmenopausal), postmenopausal hormone therapy
(yes, no), hysterectomy (yes, no), including alcohol con-
sumption, all at enrollment. We calculated average con-
sumption of alcohol in g/day based on the content of pure
alcohol in different sorts of beverages and usual portion
sizes in Norway among drinkers. Women who reported to
be teetotalers and those answering ‘‘seldom’’ or ‘‘never’’
had their alcohol consumption set to zero.
Follow-up and endpoints
We followed the women through linkages to the Norwe-
gian Central Population Register, utilizing the unique
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national birth number to identify all cases of deaths and
emigrations. The end point in our study was death from any
cause during follow-up, which ended December 31st, 2008.
All causes of death were coded according to the original
codes in the International Classification of Diseases, Ninth
Revision (ICD-9) before 1996 and the original codes of the
ICD-10 from 1996 and after. The deaths were classified
into three main outcome categories: death from cancer
(C00–C97), cardio-vascular diseases (CVDs) (I00–I99),
respiratory diseases (J00–J99). The other deaths were col-
lapsed in one group.
Cancer deaths were further classified into: (1) lung
cancer (C34), (2) other smoking-related cancers [5], which
included oral cavity (C00–C08), oropharynx (C09, C10,
C12–C14), nasopharynx (C11), esophagus (C15), stomach
(C16), colorectal (C18–C21), liver (C22), pancreas (C25),
nasal cavity and sinuses (C30, C31), larynx (C32), uterine
cervix (C53), kidney (C64), lower urinary tract (C65–C68)
and myeloid leukemia (C42) and (3) remaining cancers not
established to be smoking-related [5]. Deaths from CVDs
and respiratory diseases were further classified into: (1)
myocardial infarction (MI), (I21–I22), (2) cerebrovascular
diseases (I60–I69), (3) remaining circulatory diseases and
(1) COPD (J40–J44), (2) remaining respiratory diseases,
respectively.
Statistical analysis
We used Poisson regression models (with attained age
between cohort entry and exit as the underlying time var-
iable) to obtain adjusted relative risks (RRs) with two-sided
95 % Wald confidence intervals (CI) that compared cate-
gories of smokers (current, former, ever) with never
smokers treated as a fixed reference group. We fitted
regression models by splitting the follow-up-time into
1-year intervals [20]. Risk time was counted from date of
enrolment until censoring due to death, emigration or end
of follow-up (December 31st, 2008), whichever occurred
first. We estimated the age- and multivariable adjusted
association between smoking status at enrolment and
mortality overall and for 11 selected categories of disease
outcome.
We included the following variables; years of education
(\10,10–12, C13), BMI (\18.5, 18.5–24.9, 25–29.9,
C30 kg/m2), menopausal status (pre-, peri-, postmeno-
pausal, postmenopausal hormone therapy, hysterectomy),
alcohol consumption (0,[0–4, C5 g/day) all at enrolment,
and birth cohort (1927–1936,1937–1946,1947–1956,
1957–1965), decided a priori, for potential confounding the
smoking and mortality association.
To indicate what proportion of the deaths in the popu-
lation that would not occur if smoking were eliminated we
calculated the PAF as described in the WHO global report
[4], using the formula:
PAF ¼ PeðRRe  1Þ
Pe  RRe þ ð1  PeÞ
where the notation Pe = the proportion of persons in the
population exposed to the risk factor i.e. ever smokers and
RRe = the RR in the exposed compared to the unexposed
group; i.e. ever compared with never smokers. We calcu-
lated the two-sided 95 % CI’s for the PAF’s using the delta
method [21]. All statistical tests were two-sided and were
considered statistically significant at p B 0.05. The SAS
software version 9.22 was used for all statistical analyses.
Results
Altogether 2,842 deaths occurred during the approximately
1.2 million woman-years of observation with a mean fol-
low-up time of 14 years. Among the deaths, 1,800 (63 %)
were due to cancer, 426 (15 %) due to CVD, 108 (4 %) due
to respiratory diseases and 508 (18 %) to remaining causes.
Overall, 65 % (n = 55,227) of the women reported to be
ever (35 % current and 30 % former) smokers.
Table 1 shows the distribution of selected characteristics
according to smoking status at enrollment. Current smokers
were younger, had fewer years of education, a lower BMI
and consumed more alcohol than never smokers (Table 1).
Compared with never smokers, former smokers had a
34 % (RR = 1.34; 95 % CI 1.21–1.49) and current
smokers a more than double (RR = 2.34; 95 % CI
2.13–2.62) overall mortality rate.
Both former and current smokers had, compared with
never smokers, a significantly increased mortality rate from
Table 1 Distribution of selected characteristics given as mean (SD)a
and percentages (%) according to smoking status, all at enrollment,




Age at enrollment (years)a 46 (9.2) 46 (8.7) 44 (7.9)
Age at cohort exit (years)a 61 (8.4) 60 (8.0) 58 (7.7)
Person years of follow-upa 14 (4.0) 14 (4.1) 14 (4.4)
Education (years)a 12 (3.6) 12 (3.4) 11 (3.1)
BMI at enrollmenta 24 (3.7) 24 (3.7) 23 (3.6)
Teetotallers (%) 40 23 22
Alcohol consumption (g/day)b 2 (3.9) 3 (5.8) 4 (7.0)
SD standard deviation, BMI body mass index
a Given as mean (SD)
b Among drinkers
The hazards of death due to smoking 801
123
Table 2 Age- and multivariablea adjusted overall and selected cause-specific relative risk (RR) of mortality according to smoking status at
enrollment, Norwegian Women and Cancer (NOWAC) Study 1991–2008 (N = 85,320)
Smoking status
Never Former Current
n = 30,093 n = 25,309 n = 29,918
Mortality (n) RR RR 95 % CI RR 95 % CI
Overall mortality
Cases (N = 2842)
Age adjusted 1.00 1.31 1.18–1.45 2.35 2.15–2.57
Multivariablea 1.00 1.34 1.21–1.49 2.34 2.13–2.62
Three main outcome categories
Total cancer
Cases (N = 1800)
Age adjusted 1.00 1.15 1.02–1.30 1.91 1.70–2.13
Multivariablea 1.00 1.17 1.03–1.33 1.89 1.68–2.13
Total cardiovascular diseases
Cases (N = 426)
Age adjusted 1.00 1.57 1.19–2.06 3.67 2.87–4.68
Multivariablea 1.00 1.35 1.22–1.29 4.07 3.15–5.26
Total respiratory diseases
Cases (N = 108)
Age adjusted 1.00 3.47 1.72–6.99 10.78 5.68–20.45
Multivariablea 1.00 3.55 1.74–7.27 9.22 4.72–18.00
Selected cause-specific categories
Lung cancer
Cases (N = 298)
Age adjusted 1.00 2.82 1.72–4.63 4.89 3.59–6.67
Multivariablea 1.00 2.40 1.43–4.03 12.16 7.80–19.01
Other smoking-related cancersb
Cases (N = 764)
Age adjusted 1.00 1.22 1.01–1.47 1.82 1.53–2.16
Multivariablea 1.00 1.24 1.03–1.51 1.81 1.50–2.17
Remainingc cancers
Cases (N = 738)
Age adjusted 1.00 0.96 0.80–1.14 1.01 0.84–1.22
Multivariablea 1.00 1.07 0.90–1.27 1.09 0.90–1.31
Circulatory diseases
Cases (N = 141)
Age adjusted 1.00 2.10 1.24–3.55 5.62 3.52–8.96
Multivariablea 1.00 2.07 1.21–3.55 5.92 3.62–9.68
Myocardial infarction
Cases (N = 103)
Age adjusted 1.00 1.25 0.68–2.27 3.61 2.20–5.92
Multivariablea 1.00 1.11 0.59–2.09 3.65 2.18–6.15
Cerebrovascular disease
Cases (N = 182)
Age adjusted 1.00 1.47 1.00–2.17 2.74 1.92–3.92
Multivariablea 1.00 1.40 0.93–2.11 3.30 2.21–4.82
Chronic obstructive pulmonary diseases
Cases (N = 68)
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all three main outcome categories; cancer-, cardiovascu-
lar—and respiratory diseases. The association between
smoking and the different mortality outcomes displayed in
Table 2 was stronger for current than for former smokers.
The highest increased mortality rate was from COPD
(RR = 17.00; 95 % CI 5.90–48.78) when current was
compared with never smokers (Table 2).
Table 3 shows that the PAF of deaths among ever
smokers was 34 % (95 % CI 30–39) compared with never
smokers. The corresponding figure for lung cancer was
79 % (95 % CI 72–86) and for COPD 85 % (95 % CI
73–97) (Table 3).
Discussion
Our study shows that compared with never smokers, both
former and current smokers at cohort enrollment in the
1990s have an increased risk of dying overall, as well as
dying from the three main outcome categories; total cancer,
total CVD and total respiratory diseases. The increased risk
was more pronounced for current than for former smokers
indicating the effects of quitting smoking. One in three
deaths in this female population may be attributed to
smoking and could have been avoided if the women did not
smoke.
As we do, recent studies [13–15, 22–27], including Cau-
casian women born in the 1940’s or later, found a more than
doubling in the all-cause mortality rate, when comparing
current with never smokers. Corresponding figures have for
the first time emerged among Japanese women [28].
In our study, except for cancers not established to be
smoking-related [5], current smoking was associated with
an significantly increased risk of mortality from all cate-
gories of cause-specific mortality examined (lung cancer,
other smoking-related cancers, circulatory diseases, MI,
cerebrovascular diseases, COBP, and other respiratory
diseases).
We find a three-fold mortality rate among current
smokers compared with that of never smokers for cere-
brovascular diseases and MI, similar to those displayed in
the Nurses’ Health study [25]; and in the Million Women
Study [13], while our mortality rate from COPD and from
lung cancer was much lower than in the other two studies.
The US study [25], had more than 12,000 deaths during a
follow-up time of 24 years, while the UK study [13], had
66,000 deaths after 12 years. Both studies [25] had a RR of
mortality from lung cancer of more than 20, while the
mortality rate from COPD was 40 and 35, respectively. We
expect that the deaths related to lung cancer and COPD,
which have a long natural history, will increase when we
have a longer follow-up time. Also, Kenfield et al. [26]
showed in a later follow-up study that exposure assessed
only at enrollment, underestimated the mortality risk due to
smoking, compared with a second assessment during fol-
low-up, especially for COPD and lung cancer.
The PAF of mortality due to smoking among Norwegian
women has previously been estimated to be less than 20 %
when mortality rates from lung cancer were used as an
indirect measure of cigarette smoking [4, 12, 29], when
cohort studies from the mid-70 s were used [23] and when




n = 30,093 n = 25,309 n = 29,918
Mortality (n) RR RR 95 % CI RR 95 % CI
Age adjusted 1.00 5.40 1.79–16.27 22.00 7.91–61.22
Multivariablea 1.00 5.02 1.63–15.48 17.00 5.90–48.78
Other respiratory diseases
Cases (N = 40)
Age adjusted 1.00 2.33 0.92–5.93 4.56 1.92–10.82
Multivariablea 1.00 2.71 1.05–6.98 4.51 1.78–11.42
BMI body mass index, IARC International Agency for Research on Cancer
a Adjusted for education (\10,10–12, C13 years), BMI (\18.5,18.5–24.9, 25–29.9, C30 kg/m2), menopausal status (pre-, peri-, postmenopausal,
postmenopausal hormone therapy, hysterectomy), alcohol consumption (0, [0–4, C5 g/day), all at enrollment and birth cohort
(1927–1936,1937–1946, 1947–1956, 1957–1964)
b Smoking-related cancers according to IARC 2012; i.e. oral cavity (C00–C08), oropharynx (C09, C10, C12–C14), nasopharynx (C11),
esophagus (C15), stomach (C16), colorectal (C18–C21), liver (C22), pancreas (C25), nasal cavity and sinuses (C300, C31), larynx (C32), uterine
cervix (C53), kidney (C64), lower urinary tract (C65–C68) and myeloid leukemia (C42), excluding lung cancer (C34)
c Remaining cancers not established to be smoking-related according to IARC 2012
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Norwegian Central Bureau of Statistics were used [8, 30]
Thun et al. [12], estimated that in 2009, the PAF of mor-
tality due to smoking was highest (26–30 %) among
women aged 35–69 years, in The Netherlands, Denmark,
Hungary and Canada. In our study, based on individual
data on both exposure and outcome, the corresponding
PAF was estimated to be 34 % in Norway in 2008, with the
upper limit of the 95 % CI as high as 39 %.
The life expectancy for Norwegian females was more
than 83 years in 2008 [31]. The low background mortality
rate for women, which is the denominator of our RRs, leads
to greater PAF’s of mortality due to smoking. Our finding
of a high proportion of deaths that could have been avoided
if nobody was smoking is in accordance with the rapidly
increasing lung cancer incidence for Norwegian women.
The age adjusted world lung cancer incidence rate more
than doubled from 11.7 per 100,000 person-years in the
5-year period (1986–1990) immediately before the com-
mencement of our study to 25.1 per 100,000 person-years
for the current 5 year period including the year which our
follow-up ended [10]. This increasing lung cancer inci-
dence also tells us that the PAF of mortality due to smoking
among Norwegian women has not peaked yet.
As pointed out by Jha [3], the full effects of smoking can
take 50 years to measure in individuals, and up to
100 years to measure in populations. Our study shows the
PAF due to smoking among females already to be higher
than the peak in the gender specific model recently
developed by Thun et al. [12].
Table 3 Overall and selected cause-specific mortalitya among ever
compared with never smokers at enrollment, and the population
attributable fraction (PAF) (%) of smoking with confidence intervals




n = 30,093 n = 55,227 % CI
All-cause mortality 34 30–39




Total cancer 24 18–31





Relative risk 1.00 2.52
1.99–3.20
Total respiratory diseases 76 63–88




Lung cancer 79 72–86
Relative risk 1.00 6.87
4.46–10.60
Smoking-related cancersb 24 14–34
Relative risk 1.00 1.49
1.27–1.76
Remainingc cancers 3 0.9–15
Relative risk 1.00 1.05
0.89–1.23
Circulatory diseases 63 49–77
Relative risk 1.00 3.59
2.26–5.69
Myocardial infarction 43 21–65
Relative risk 1.00 2.17
1.33–3.54
Cerebrovascular diseases 42 25–58





Relative risk 1.00 9.87
3.53–27.64
Other respiratory diseases 61 34–88




n = 30,093 n = 55,227 % CI
1.45–7.99
BMI body mass index, IARC International Agency for Research on
Cancer
a Adjusted for education (\10,10–12, C13 years), BMI
(\18.5,18.5–24.9, 25–29.9, C30 kg/m2), menopausal status (pre-,
peri-, postmenopausal, postmenopausal hormone therapy, hysterec-
tomy), alcohol consumption (0, [0–4, C5 g/day), all at enrollment
and birth cohort (1927–1936,1937–1946, 1947–1956, 1957–1964)
b Smoking-related cancers according to IARC 2012; i.e. oral cavity
(C00–C08), oropharynx (C09, C10, C12–C14), nasopharynx (C11),
esophagus (C15), stomach (C16), colorectal (C18–C21), liver (C22),
pancreas (C25), nasal cavity and sinuses (C300, C31), larynx (C32),
uterine cervix (C53), kidney (C64), lower urinary tract (C65-C68) and
myeloid leukemia (C42), excluding lung cancer (C34)
c Remaining cancers not established to be smoking-related according
to IARC, 2012
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Strengths
The most important strength of our study is that it is a
nationally representative prospective cohort study allowing
us to calculate the PAF of mortality due to smoking for
middle-aged women. We know from our previous studies
that the smoking exposure [17, 32, 33] and the cancer
incidence [19] reflect known smoking patterns [8, 9] and
cancer incidence [10] for Norwegian women. Thus, we are
confident that our cohort is representative of the Norwegian
female population, born between 1926 and 1965, both
according to exposure and outcome of this study.
Other major strengths of our study are; we have a high
proportion of both current and former smokers, virtually
complete follow-up through the National population based
registries and the possibility of examining the association
with smoking according to both all-cause and cause-spe-
cific mortality. Another force is that we focus our PAF
estimates on the comparison between ever versus never
smokers. Thus, it is only never smokers that could possibly
change smoking status during follow-up. Since very few
Norwegians start to smoke after the age of 30 and the mean
age at enrolment for our study is more than 40 years, we
are confident that the possible changes in smoking status
among the never smokers during follow-up did not influ-
ence our PAF estimates. Furthermore, we have detailed
information on, and were able to control for alcohol con-
sumption and BMI, which are established risk factors for
mortality.
Limitations
One major limitation of this report is that we have a limited
number of deaths. Furthermore, 9 % of the women had
missing values for physical activity levels and therefore
this variable was not included in the multivariable analyses
as there was no difference in physical activity levels
according to smoking status. As in our study, neither of the
seven [13–15, 25, 26, 34, 35] recently published studies did
find much effect of confounding when they compared the
effect of smoking on mortality. Five of these studies were
conducted in the US [14, 15, 25, 26, 34]; one in the UK
[13], and one in China [35]. We found a small non-sig-
nificantly increased risk of deaths from cancers not estab-
lished to be associated with smoking. This may be due to
chance or that breast cancer should be in the category for
smoking-related cancers. According to the most recent
IARC monograph cigarette smoking is possibly carcino-
genic to the human breast [5]. After this monograph was
published two large cohort studies, one from the US [36],
and our own Norwegian study [37] based on more than
300,000 women, conclude that smoking initiation before
the first childbirth increase the risk of breast cancer.
Other limitations are that we have not validated self-
reported information on height and body weight and that
the current PAF formula does not provide a fully adjusted
estimate of PAF due to lack of adjustment of the preva-
lence. We chose not to exclude women with prevalent
disease as a previous study from the same cohort which
examined physical activity and mortality found basically
the same results when they did their analyses with and
without women with prevalent disease at enrolment [38].
This has most likely deflated or RR estimates of mortality.
Given the reduction in life expectancy associated with
smoking we cannot rule out that part of the cause-specific
associations is hidden or obscured by the competing causes
of death with increasing age. We do not expect that the
changes in BMI or alcohol consumption during follow-up
would influence our results to any great extent. Neverthe-
less, we cannot rule out the possibility of residual con-
founding due to the above described factors, or other
factors we did not measure.
In summary, one in three deaths among middle aged
women in Norway could have been prevented if the women
did not smoke. More middle-aged women, than ever
before, are dying prematurely due to smoking in Norway.
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